Moderna, Inc.
200 Technology Square
Cambridge, MA
United States
Tel: 617-714-6500
Website: https://modernatx.com/
Email: careers@modernatx.com
About Moderna, Inc.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
mRNA is now a turning point in the history of science, medicine, technology, even humankind itself. With this breakthrough discovery, many of the world’s biggest and most challenging medical problems are no longer a question of “how?” but merely a question of “when?”
Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine.
Stock Symbol:
MRNA
Stock Exchange:
USNASDAQ GS
Moderna employees share their thoughts on our culture, values and mission. To hear additional employee stories and learn more about our inclusive and innovative benefits offerings, visit us on our website.
1148 articles about Moderna, Inc.
-
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
9/11/2023
Moderna, Inc.. (NASDAQ:MRNA, "Moderna") and Immatics N.V. (NASDAQ:IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need.
-
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
9/11/2023
Moderna, Inc. (NASDAQ: MRNA, “Moderna”) and Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high unmet medical need.
-
Moderna Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
9/8/2023
Moderna, Inc. (Nasdaq:MRNA) has been notified that TRC Capital Investment Corporation (TRC Capital) has made an unsolicited "mini-tender" offer to purchase up to 1,000,000 shares of Moderna's common stock, at an offer price of $107.56 per share.
-
Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference
9/6/2023
Moderna, Inc. (Nasdaq:MRNA), today announced its participation in a fireside chat at Morgan Stanley's 21st Annual Global Healthcare Conference on Tuesday, September 12th at 12:15 p.m. ET.
-
The vaccine maker reported new trial data confirming an 8.7 to 11-fold increase in neutralizing antibodies against circulating strains, including the highly watched BA.2.86, EG.5 and FL.1.5.1 variants.
-
Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86
9/6/2023
Moderna, Inc. announced that clinical trial data from its research assay confirm its updated COVID-19 vaccine, which is pending approval by the U.S. Food and Drug Administration for the fall 2023 vaccination season, generates an 8.7-fold increase in neutralizing antibodies in humans against BA.2.86, a variant under monitoring.
-
In the latest salvo, Pfizer and BioNTech fired back at Moderna and asked the U.S. Patent and Trademark Office to invalidate patent claims over the COVID-19 vaccines they say are overly broad.
-
Moderna to Host Investor Event - R&D Day and Business Updates
8/30/2023
Moderna, Inc. announced that it will host its Investor Event - R&D Day and Business Updates at 1:00 p.m. ET on Wednesday, September 13, 2023.
-
The companies will evaluate Moderna’s investigational Claudin18.2 mRNA cancer vaccine in combination with CARsgen’s Claudin18.2 CAR T cell candidate.
-
The companies contend that their updated COVID-19 vaccines for the fall vaccination season can elicit strong immune responses against the virus’ currently dominant and emerging subvariants.
-
Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants
8/17/2023
Moderna, Inc. announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023 vaccination season showed a significant boost in neutralizing antibodies against EG.5 and FL.1.5.1 variants.
-
Week in Review: Breakthrough Depression Drug, RSV and GLP-1 Lawsuits, and Earnings Season Shows C...
8/4/2023
A transformational moment in the treatment of depression, GSK takes first shot in a vaccine patent war with Pfizer, a Louisiana woman sues Novo Nordisk and Lilly, and companies face a steep COVID-19 cliff. -
Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates
8/3/2023
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, reported financial results and provided business updates for the second quarter of 2023.
-
The biotech Thursday reported that second-quarter sales of its COVID shot dropped 94%. However, it expects $6 billion to $8 billion in revenue this year, up from a previous forecast of $5 billion.
-
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
7/26/2023
Merck, known as MSD outside of the United States and Canada, and Moderna, Inc. announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940, an investigational individualized neoantigen therapy, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-risk melanoma.
-
The Phase III trial, which will test the companies' mRNA-based personalized cancer vaccine and Merck’s blockbuster Keytruda checkpoint inhibitor, is slated for completion by the fall of 2029.
-
Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
7/13/2023
Moderna, Inc. today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 3, 2023 to report its second quarter 2023 financial results, and provide a corporate update.
-
The company has signed a memorandum of understanding and land collaboration agreement to develop medicines exclusively for Chinese use.
-
Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345
7/5/2023
Moderna has submitted marketing authorization applications for the investigational RSV vaccine, mRNA-1345, with the European Medicines Agency, Swissmedic, and the Therapeutic Goods Administration in Australia.
-
MODERNA INITIATES ROLLING SUBMISSION TO HEALTH CANADA FOR UPDATED COVID-19 VACCINE
6/29/2023
Moderna, Inc. (NASDAQ: MRNA) today announced that it has initiated the filing of a rolling New Drug Submission (NDS) to Health Canada for its updated monovalent COVID-19 vaccine, SPIKEVAX® XBB.1.5 (mRNA-1273.815) targeting the omicron subvariant XBB.1.5 of SARS-CoV-2.